Cargando…

mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials

We evaluated if standard hormonal therapy (HT) could be improved by the addition of mammalian target of rapamycin inhibitors (mTOR-I) in metastatic luminal breast cancer. A meta-analysis on 4 phase II-III randomized clinical trials was performed. Pooled hazard ratio (HR) for progression free surviva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rotundo, Maria Saveria, Galeano, Teresa, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053632/ https://www.ncbi.nlm.nih.gov/pubmed/26895472 http://dx.doi.org/10.18632/oncotarget.7446

Ejemplares similares

Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer
por: Correale, Pierpaolo, et al.
Publicado: (2012)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
por: Siciliano, Maria Anna, et al.
Publicado: (2020)

DMET(TM) Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine
por: Agapito, Giuseppe, et al.
Publicado: (2020)

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities
por: Botta, Cirino, et al.
Publicado: (2014)

Analysis of miRNA, mRNA, and TF interactions through network-based methods
por: Guzzi, Pietro H, et al.
Publicado: (2015)

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
por: Alvarez-Lopez, I., et al.
Publicado: (2020)

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
por: Tagliaferri, Pierosandro, et al.
Publicado: (2009)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
por: Amodio, Nicola, et al.
Publicado: (2015)

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
por: Amodio, Nicola, et al.
Publicado: (2018)

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes
por: Agapito, Giuseppe, et al.
Publicado: (2016)

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
por: Arbitrio, Mariamena, et al.
Publicado: (2016)

DMET-Analyzer: automatic analysis of Affymetrix DMET Data
por: Guzzi, Pietro Hiram, et al.
Publicado: (2012)

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221
por: Di Martino, Maria Teresa, et al.
Publicado: (2019)

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
por: Staropoli, Nicoletta, et al.
Publicado: (2013)

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers
por: Settino, Marzia, et al.
Publicado: (2020)

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
por: Raimondi, Lavinia, et al.
Publicado: (2016)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Depletion of Luminal Pyridine Nucleotides in the Endoplasmic Reticulum Activates Autophagy with the Involvement of mTOR Pathway
por: Kapuy, Orsolya, et al.
Publicado: (2013)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
por: Yanagawa, Masumi, et al.
Publicado: (2012)

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
por: Di Martino, Maria Teresa, et al.
Publicado: (2021)

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
por: Holloway, Ryan W., et al.
Publicado: (2021)

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
por: Caracciolo, Daniele, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2016)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

PD-1/PD-L1 blockade, a novel strategy for targeting metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials
por: Rotundo, Maria Saveria, et al.
Publicado: (2022)

Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer
por: Gandhi, Nishant, et al.
Publicado: (2021)

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation
por: Staropoli, Nicoletta, et al.
Publicado: (2016)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes
por: Scionti, Francesca, et al.
Publicado: (2022)

Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR
por: Zhang, Baotong, et al.
Publicado: (2015)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment
por: Zarone, Mayra Rachele, et al.
Publicado: (2017)

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice
por: Ascrizzi, Serena, et al.
Publicado: (2023)

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
por: Yang, Zheng‐Jun, et al.
Publicado: (2022)

A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
por: Yang, Xue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_45r9rbldssl5kjvn23g7corlg3